New research bolsters a connection between the risk for cancer before and after peripartum cardiomyopathy (PPCM) and identifies genetic variants underlying PPCM and a variety of cancers.
"This study is the first to describe a markedly increased risk for malignancies both before and after the diagnosis of PPCM," TobiasJ. Pfeffer, MD, Hannover Medical School, Germany, and colleagues observe.
PPCM develops in about one in 1500 previously healthy women worldwide and is a leading cause of peripartum maternal death. Some studies have identified truncating mutations in the gene TTN in a subset of women, whereas others have shown that blocking prolactin release with bromocriptine may remove a key driver of the disease by preventing the generation of a toxic 16-kDa prolactin fragment from the nursing hormone prolactin.
"We have made a lot of progress on treating PPCM, but we still have large gaps in knowing why this disease happens to young women," senior study author Denise Hilfiker-Kleiner, PhD, also from the Hannover Medical School, told theheart.org| Medscape Cardiology.
She noted that although cardiotoxic cancer therapies have been linked to a higher risk for PPCM, the team was also seeing an increase in early-onset cancer in women after PPCM at their institution.
At the same time, a large Swedish population study reported that elevated cardiac and inflammatory biomarkers in healthy individuals predicted new-onset cancer, independent of age, smoking status, and body mass index.
To examine the prevalence of cancer and a possible genetic overlap between the two diseases, the researchers compared data from 236 German and Swedish PPCM patients with age-matched patients from a German cancer registry. Median follow-up was 33 months (range, 5 months to 19 years).
The prevalence of cancer was 16-fold higher in women with a history of PPCM than in their age-matched peers without PPCM (8.9% vs 0.59%; odds ratio [OR], 16.4; 95% confidence interval, 10.5- 25.7), the authors reported December17 in JACC: CardioOncology.
Among the 12 patients diagnosed with cancer before PPCM, 11 had received chemotherapy and/or radiation in childhood or adolescence, but none showed signs of heart failure after cancer treatment or prior to pregnancy.
During follow-up, however, only 17% of patients with a cancer diagnosis before PPCM fully recovered defined as a left ventricular ejection fraction (LVEF) of at least 50% compared with 55% of PPCM patients without cancer.
Among the 10 PPCM patients with a cancer diagnosis after PPCM, seven displayed normal LV function after cancer therapy. Compared with the age-matched women without PPCM, the risk for cancer was still eightfold higher after PPCM (OR, 8.5; 95% CI, 4.5- 16.1).
To examine what might be driving PPCM and cancer in these patients, researchers analyzed whole-exome-sequencing data available for a subset of 14 PPCM patients, 10 of whom developed cancer before and three after the onset of PPCM.
The results showed that 43% of patients carried gene variants likely pathogenic or pathogenic (LP/P) for dilated or hypertrophic cardiomyopathy (DCM/HCM) and/or cancer predisposition syndrome (CPS).
In 11 patients, variants of unknown significance (VUS) and likely pathogenic/pathogenic variants associated with cardiomyopathy were detected in eight genes: CPT2, DSG2, DSP, MYBPC3, MYH7, RYR1, TTN, and TXNRD2.
In seven of the 14 patients, VUS and likely pathogenic/pathogenic variants were found in eight other genes ATM, BRCA1, ERCC5, FANCA, NBN, POLD1, RECQL4, and SLX4 all of which are involved in DNA-damage repair (DDR).
"We are far away from having this complete because exome sequencing in larger cohorts is not financially an easy task, but it is interesting that from 30 additional PPCM patients without cancer, we did not find a CPS mutation in a single one," Hilfiker-Kleiner said. "So I think this cancer predisposition pathway is a really interesting aspect of the results."
"It is striking that they all map in a single pathway: the DNA repair pathway," she said. "It's quite a crucial pathway and if mutated can lead to all sorts of cancers."
Indeed, cancers in the 21 PPCM patients varied widely, from osteosarcoma to acute myeloid leukemia, with one patient developing Hodgkin's lymphoma before PPCM and breast cancer after PPCM, noted Hilfiker-Kleiner.
Although the patient numbers are small, the absence of DDR variants in PPCM patients without cancer "may still be an interesting lead" because variants in ATM and BRCA1 may promote heart failure, including from anthracycline cardiotoxicity, through an impaired stress response, Jean-Luc Balligand, MD, PhD, UCLouvain and Cliniques Universitaires Saint-Luc, Brussels, said in a related editorial.
"For PPCM patients with a cancer history, the observation of LP/P or variants of unknown significance for CPS/DDR genes in one-half of them is intriguing and novel, and it deserves confirmatory longitudinal studies in childhood/adolescent cancer survivors to verify if they predispose to PPCM with or without cancer recurrence," he said.
With regard to PPCM possibly promoting cancer, Balligand also highlighted the link between cardiac and inflammatory biomarkers and new-onset cancer, and noted that in the context of the present study, it is plausible that women with CPS/DDR variants, and thus a genetic background for neoplastic disease, developed cancer in the wake of PPCM and heart failure.
"These observations may well have far-reaching implications, not only for the understanding of the pathogenic mechanisms of PPCM and cancer development in patients with heart failure, but also for the clinical care of women with a history of PPCM or cancer who become pregnant," he said.
Both the editorialist and the researchers say the data support close monitoring of LV function in women with a history of cancer who become pregnant, and cancer screening at least for the next 5 or 10 years in women who develop PPCM.
"The mechanistic connection of these two diseases should trigger that both fields, cardiology and oncology, are aware that this exists and counsel their patients and sensitize them for the disease of the other discipline," Hilfiker-Kleiner said.
Although PPCM cannot be prevented, current guidelines give a classIIb recommendation to add bromocriptine to standard heart failure therapies, she noted. This was done in three-fourths of PPCM patients in the study, with only one patient, who did not receive bromocriptine, requiring transplant.
Limitations of the study are the observational design, which prevents determining causality, and the small number of genetic results, Hilfiker-Kleiner said.
"We are a translational lab and what we are doing is breeding mice that have mutations in this DNA damage pathway to see if they will develop PPCM, which would support the idea that the cancer predisposition variants we found in our patients are also responsible for the PPCM the patients have," she said. "We also developed a model where we can induce heart failure in mice to see if the heart failure will lead to an early onset of cancer in individuals that carry these cancer predisposition mutations."
"Even though it was only 14 patients, the observation that all these mutations mapped in this DNA damage repair pathway, we believe, is not by chance," she added.
The study was supported by grants from the Deutsche Forschungsgesellschaft, the Bundesministerium fr Bildung und Forschung, and DGK-Oskar-Lapp. The authors and Balligand report having no relevant conflicts of interest.
JACC: CardioOncology. 2019;1:196-205 and 206-207. Full text, Editorial
Follow Patrice Wendling on Twitter: @pwendl. For more from theheart.org| Medscape Cardiology, join us on Twitter and Facebook.
Continue reading here:
The Unholy Pairing of Cancer and Peripartum Cardiomyopathy - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]